-transparent.png){kind=logo}
Defective natural killer (NK) cell populations from patients with chronic myelogenous leukemia (CML), that reacted with both HNK-1+ and B73.1+ antibodies, were obtained by a fluorescence-activated cell sorter (FACS). These fractions, along with NK fractions from normal donors which reacted with both antibodies, were expanded as bulk cultures or clones by limiting dilution, for 4 weeks in the presence of 10% interleukin 2 (IL 2), human type AB plasma, and irradiated human allogeneic mononuclear cells. Successfully established clones from patients with CML, with lytic activity against autologous and more differentiated neoplastic granulocytes, were generated more efficiently from B73.1+ than from HNK-1+ subsets. However, there were no significant differences among the generations of B73.1+ and HNK-1+ clones for both patients and normal donors with lytic activity against NK susceptible K-562 targets. Fresh myeloblast preparations from a blast crisis were found to be more susceptible to lysis by IL 2-proliferative B73.1+ and HNK-1+ clones than were fresh myelocyte preparations from a chronic phase CML patient, which were lytically susceptible to only B73.1+ clones. B73.1+ and HNK-1+ subsets from CML patients demonstrated major histocompatibility complex nonrestricted killing, and showed the following predominant phenotypes: B73.1+T3+T8+ or B73.1+T3+T8- from B73.1+ subsets; and HNK-1-T3+T8+ (initially HNK-1+) from HNK-1+ subsets. In contrast, B73.1+ and HNK-1+ clones from normal donors showed the following predominant phenotypes: B73.1+T3-T8-; and HNK-1-T3-T8- or HNK-1-T3-T8+ (initially all HNK-1+). Short-term in vitro IL 2 or interferon treatment of fresh NK defective subsets from CML patients resulted in minimal cytotoxic augmentation. In contrast, defective NK cells from CML patients, whether HNK-1+ or B73.1+ subsets, proliferated with complete regeneration of cytolytic activity after a 3-4 week exposure to IL 2, but differed in phenotypic profiles as compared to those of normal donors. These observations imply that not only fresh defective NK cells but also the cytotoxically restored clones from CML patients are derived from different NK subsets and may represent undifferentiated forms of NK cells that may be arrested at an early stage of development by yet unknown mechanism(s). In vitro substantiation of autologous leukemia cell killing by IL 2-proliferative NK cell clones is encouraging and may allow for new in vivo immunotherapeutic modalities in CML patients.
Y Fujimiya, and
W C Chang, and
A Bakke, and
D Horwitz, and
P K Pattengale
November 1997,
Leukemia & lymphoma,
Y Fujimiya, and
W C Chang, and
A Bakke, and
D Horwitz, and
P K Pattengale
October 2019,
Iranian journal of allergy, asthma, and immunology,
Y Fujimiya, and
W C Chang, and
A Bakke, and
D Horwitz, and
P K Pattengale
January 2000,
Acta haematologica,
Y Fujimiya, and
W C Chang, and
A Bakke, and
D Horwitz, and
P K Pattengale
December 1989,
American journal of hematology,
Y Fujimiya, and
W C Chang, and
A Bakke, and
D Horwitz, and
P K Pattengale
January 1983,
Birth defects original article series,
Y Fujimiya, and
W C Chang, and
A Bakke, and
D Horwitz, and
P K Pattengale
August 1991,
British journal of haematology,
Y Fujimiya, and
W C Chang, and
A Bakke, and
D Horwitz, and
P K Pattengale
August 1995,
Leukemia & lymphoma,
Y Fujimiya, and
W C Chang, and
A Bakke, and
D Horwitz, and
P K Pattengale
July 1999,
Leukemia research,
Y Fujimiya, and
W C Chang, and
A Bakke, and
D Horwitz, and
P K Pattengale
January 2006,
Annals of clinical and laboratory science,
Y Fujimiya, and
W C Chang, and
A Bakke, and
D Horwitz, and
P K Pattengale
April 2004,
Leukemia,
